577778-58-6 | Topiroxostat

Packsize	Purity	Availability	Price	Discounted Price
50mg	98%	in stock	$7.00	$5.00
100mg	98%	in stock	$9.00	$6.00
1g	98%	in stock	$36.00	$25.00
5g	98%	in stock	$149.00	$104.00

Description

• Catalog Number: AB62991
• Chemical Name: Topiroxostat
• CAS Number: 577778-58-6
• Molecular Formula: C13H8N6
• Molecular Weight: 248.2428
• MDL Number: MFCD17167057
• SMILES: N#Cc1nccc(c1)c1[nH]nc(n1)c1ccncc1

Computed Properties

• Complexity: 344
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 19
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 2
• XLogP3: 1.2

Literature

• Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout.

  Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 20150101

• QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation.

  Journal of clinical pharmacology 20140401

• Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.

  Clinical and experimental nephrology 20140101

• Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.

  Archives of toxicology 20110501

• Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.

  Drug and chemical toxicology 20110401

• Study on toxicological aspects of crystal-mediated nephrotoxicity induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.

  Drug and chemical toxicology 20110401

• FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase.

  The Journal of pharmacology and experimental therapeutics 20110101

• Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].

  Bioorganic & medicinal chemistry letters 20091101

• FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeys.

  Toxicologic pathology 20090601

• [Inhibitors of xanthine oxidoreductase].

  Nihon rinsho. Japanese journal of clinical medicine 20080401

• [New antihyperuricemic medicine: febuxostat, Puricase, etc].

  Nihon rinsho. Japanese journal of clinical medicine 20080401

• Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20080201

• Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor.

  Drug metabolism and disposition: the biological fate of chemicals 20071201

• Strain differences in the responsiveness between Sprague-Dawley and Fischer rats to nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.

  Toxicology and applied pharmacology 20061215

• Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides.

  Drug metabolism and disposition: the biological fate of chemicals 20061101

• Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.

  Toxicological sciences : an official journal of the Society of Toxicology 20050901

• The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition.

  Proceedings of the National Academy of Sciences of the United States of America 20040525

• An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.

  The Journal of biological chemistry 20030117